Aripiprazole Sandoz

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
27-02-2024
Tabia za bidhaa Tabia za bidhaa (SPC)
27-02-2024

Viambatanisho vya kazi:

aripiprazole

Inapatikana kutoka:

Sandoz GmbH

ATC kanuni:

N05AX12

INN (Jina la Kimataifa):

aripiprazole

Kundi la matibabu:

Psycholeptics

Eneo la matibabu:

Schizophrenia; Bipolar Disorder

Matibabu dalili:

Aripiprazole Sandoz is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. Aripiprazole Sandoz is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. Aripiprazole Sandoz is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.,

Bidhaa muhtasari:

Revision: 9

Idhini hali ya:

Authorised

Idhini ya tarehe:

2015-08-20

Taarifa za kipeperushi

                                54
B. PACKAGE LEAFLET
55 PACKAGE LEAFLET: INFORMATION FOR THE USER
ARIPIPRAZOLE SANDOZ 5 MG TABLETS
ARIPIPRAZOLE SANDOZ 10 MG TABLETS
ARIPIPRAZOLE SANDOZ 15 MG TABLETS
ARIPIPRAZOLE SANDOZ 20 MG TABLETS
ARIPIPRAZOLE SANDOZ 30 MG TABLETS
aripiprazole
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even
if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not
listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Aripiprazole Sandoz tablets are and what they are used for
2.
What you need to know before you take Aripiprazole Sandoz tablets
3.
How to take Aripiprazole Sandoz tablets
4.
Possible side effects
5.
How to store Aripiprazole Sandoz tablets
6.
Contents of the pack and other information
1.
WHAT ARIPIPRAZOLE SANDOZ IS AND WHAT IT IS USED FOR
Aripiprazole Sandoz contains the active substance aripiprazole and
belongs to a group of medicines called
antipsychotics. It is used to treat adults and adolescents aged 15
years and older who suffer from a disease
characterised by symptoms such as hearing, seeing or sensing things
which are not there, suspiciousness,
mistaken beliefs, incoherent speech and behaviour and emotional
flatness. People with this condition may
also feel depressed, guilty, anxious or tense.
Aripiprazole Sandoz is used to treat adults and adolescents aged 13
years and older who suffer from a
condition with symptoms such as feeling "high", having excessive
amounts of energy, needing much less
sleep than usual, talking very quickly with racing ideas and sometimes
severe irritability. In adults it also
prevents this condition from returning in patients who have responded
to the treatment w
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Aripiprazole Sandoz 5 mg tablets
Aripiprazole Sandoz 10 mg tablets
Aripiprazole Sandoz 15 mg tablets
Aripiprazole Sandoz 20 mg tablets
Aripiprazole Sandoz 30 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Aripiprazole Sandoz 5 mg tablets
Each tablet contains 5 mg of aripiprazole.
Excipient with known effect
67.47 mg lactose (as monohydrate) per tablet.
Aripiprazole Sandoz 10 mg tablets
Each tablet contains 10 mg of aripiprazole.
Excipient with known effect
62.67 mg lactose (as monohydrate) per tablet.
Aripiprazole Sandoz 15 mg tablets
_ _
Each tablet contains 15 mg of aripiprazole.
Excipient with known effect
92.86 mg lactose (as monohydrate) per tablet.
Aripiprazole Sandoz 20 mg tablets
Each tablet contains 20 mg of aripiprazole.
Excipient with known effect
125.72 mg lactose (as monohydrate) per tablet.
Aripiprazole Sandoz 30 mg tablets
Each tablet contains 30 mg of aripiprazole.
Excipient with known effect
186.68 mg lactose (as monohydrate) per tablet.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Aripiprazole Sandoz 5 mg tablets
3
Blue coloured, mottled, round shaped tablet, with an approximate
diameter of 6.0 mm, debossed with “SZ”
on one side and “444” on the other side.
Aripiprazole Sandoz 10 mg tablets
Pink coloured, mottled, round shaped tablet, with an approximate
diameter of 6.0 mm, debossed with “SZ”
on one side and “446” on the other side.
Aripiprazole Sandoz 15 mg tablets
Yellow coloured, mottled, round shaped tablet, with an approximate
diameter of 7.0 mm, debossed with
“SZ” on one side and “447” on the other side.
Aripiprazole Sandoz 20 mg tablets
White coloured, round shaped tablet, with an approximate diameter of
7.8 mm, debossed with “SZ” on one
side and “448” on the other side.
_ _
_ _
Aripiprazole Sandoz 30 mg tablets
Pink coloured, mottled, round shaped tablet, with an approximate
diameter of 9.0 mm, debossed with “SZ”
on one side and 
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kibulgaria 27-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 25-09-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kihispania 27-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 25-09-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kicheki 27-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 25-09-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kidenmaki 27-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 25-09-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kijerumani 27-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 25-09-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kiestonia 27-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 25-09-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kigiriki 27-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 25-09-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kifaransa 27-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 25-09-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kiitaliano 27-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 25-09-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kilatvia 27-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 25-09-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kilithuania 27-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 25-09-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kihungari 27-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 25-09-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kimalta 27-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 25-09-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kiholanzi 27-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 25-09-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kipolandi 27-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 25-09-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kireno 27-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 25-09-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kiromania 27-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 25-09-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kislovakia 27-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 25-09-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kislovenia 27-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 25-09-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kifinlandi 27-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 25-09-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kiswidi 27-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 25-09-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kinorwe 27-02-2024
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 27-02-2024
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 27-02-2024
Tabia za bidhaa Tabia za bidhaa Kroeshia 27-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 25-09-2015

Tafuta arifu zinazohusiana na bidhaa hii